Cargando…
Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours
Tumours defective in the DNA homologous recombination repair pathway can be effectively treated with poly (ADP-ribose) polymerase (PARP) inhibitors; these have proven effective in clinical trials in patients with BRCA gene function-defective cancers. However, resistance observed in both pre-clinical...
Autores principales: | Ordonez, Liliana D., Hay, Trevor, McEwen, Robert, Polanska, Urszula M., Hughes, Adina, Delpuech, Oona, Cadogan, Elaine, Powell, Steve, Dry, Jonathan, Tornillo, Giusy, Silcock, Lucy, Leo, Elisabetta, O’Connor, Mark J., Clarke, Alan R., Smalley, Matthew J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498996/ https://www.ncbi.nlm.nih.gov/pubmed/31080552 http://dx.doi.org/10.18632/oncotarget.26830 |
Ejemplares similares
-
NOTCH and AKT Signalling Interact to Drive Mammary Tumour Heterogeneity
por: Ordonez, Liliana, et al.
Publicado: (2023) -
ERrrr…Where are the Progenitors? Hormone Receptors and Mammary Cell Heterogeneity
por: Tornillo, Giusy, et al.
Publicado: (2015) -
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
por: Staniszewska, Anna D., et al.
Publicado: (2022) -
Reproductive history determines Erbb2 locus amplification, WNT signalling and tumour phenotype in a murine breast cancer model
por: Ordonez, Liliana D., et al.
Publicado: (2021) -
Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)